Sign in Subscribe
Pharmaceutical industry

COVID-19 Pandemic Accelerates Development of New Therapies and Vaccines

Strategic Insights

— 2 min read

The ongoing COVID-19 pandemic has accelerated the development of new therapies and vaccines to combat the disease. Scientists are investigating various treatments, including drugs used to treat malaria and autoimmune diseases, antiviral drugs for other viruses, and antibodies from individuals who have recovered from COVID-19. However, the pandemic has also highlighted the growing impact of secondary conditions, such as Acute Respiratory Distress Syndrome (ARDS), on patients who have or have had the virus.

Key Takeaways:

  • The Global Acute Respiratory Distress Syndrome (ARDS) market size was valued at USD 618.82 Million in 2019 and is expected to reach USD 990.88 Million by the year 2027, growing at a CAGR of 6% through the forecast period (ReportsAndData).
  • Citius Pharmaceuticals' subsidiary NoveCite has announced interim data from a proof-of-concept study of its proprietary induced mesenchymal stem cell (i-MSC) therapy for acute inflammatory respiratory conditions, including COVID-19-related Acute Respiratory Distress Syndrome (ARDS).
  • Moderna, Inc. has increased its confirmed order commitment from 4.5 million to 7.5 million doses of its COVID-19 vaccine candidate, mRNA-1273.
  • INOVIO has dosed its first subject in a Phase 2 clinical trial evaluating DNA medicine INO-4800, its COVID-19 vaccine candidate, as part of its Phase 2/3 clinical trial, called INNOVATE.
  • Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate.
  • AstraZeneca PLC and Oxford University have announced that a COVID-19 vaccine developed by the two entities has shown average efficacy of 70.4% in a pooled analysis of interim data from late-stage trials.

Statistics:

  • The Global Acute Respiratory Distress Syndrome (ARDS) market size was valued at USD 618.82 Million in 2019.
  • The market is expected to reach USD 990.88 Million by the year 2027, growing at a CAGR of 6% through the forecast period.
  • Moderna, Inc. has increased its confirmed order commitment from 4.5 million to 7.5 million doses of its COVID-19 vaccine candidate, mRNA-1273.

Sources:

  • ReportsAndData: The Global Acute Respiratory Distress Syndrome (ARDS) market size was valued at USD 618.82 Million in 2019 and is expected to reach USD 990.88 Million by the year 2027, growing at a CAGR of 6% through the forecast period.
  • Citius Pharmaceuticals: Citius Pharmaceuticals' subsidiary NoveCite has announced interim data from a proof-of-concept study of its proprietary induced mesenchymal stem cell (i-MSC) therapy for acute inflammatory respiratory conditions, including COVID-19-related Acute Respiratory Distress Syndrome (ARDS).
  • Moderna, Inc.: Moderna, Inc. has increased its confirmed order commitment from 4.5 million to 7.5 million doses of its COVID-19 vaccine candidate, mRNA-1273.
  • INOVIO: INOVIO has dosed its first subject in a Phase 2 clinical trial evaluating DNA medicine INO-4800, its COVID-19 vaccine candidate, as part of its Phase 2/3 clinical trial, called INNOVATE.
  • Pfizer Inc.: Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate.
  • AstraZeneca PLC and Oxford University: AstraZeneca PLC and Oxford University have announced that a COVID-19 vaccine developed by the two entities has shown average efficacy of 70.4% in a pooled analysis of interim data from late-stage trials.

Read more